| Metric | Q1'26 | Q2'26 | Change |
|---|---|---|---|
| Net Interest Margin | 420 bps, described as 'really strong' with no caution flagged | +4 bps QoQ improvement, guided to dip below 420 in H2 | Beat driven by one-time deposit cost cut + payoff timing, guided to reverse below prior level in H2 |
| Full-year NIM/NII confidence tone | Unqualified pride in margin management, 'that 420 net interest margin we have is... really strong' | 'Cautious guidance on being able to equal or beat last year's net interest income number' | Confidence downgrade on full-year NII |
| Average Earning Assets growth trajectory | Expected easing of RESG repayment headwinds into 2027, implying a steadier growth path | Up ~2% after Q1, then negative in Q2: 'we went backwards' | Sequential miss vs internal expectation |
| RESG repayments (quarter) | Headwinds expected to persist with gradual easing into 2027 | ~$3.0B in Q2, approaching record pace, guided elevated into 2027 | Elevated payoff wave accelerating, guidance extended a full year further out |
| RESG payoffs (trailing 4 quarters) | General acknowledgment that repayment headwinds would continue | ~$10 billion ('$9.95 billion') | New absolute-dollar disclosure framed as 'massive recycling' |
| CIB loan book size vs RESG | CIB expected to equal RESG in 2027 | CIB $7B+ vs RESG $15B+, crossover still '2027' | Reaffirmed timeline, gap still 2x |
| CRE concentration / diversification rationale | Diversification framed around CIB catching RESG in size by 2027, no specific regulatory ratio cited | Now under 300% CRE regulatory guideline; C&D targeted under 100% by year-end/early 2027 | New compliance milestone disclosed |
| Full-year loan growth guidance | Growth expected to accelerate into 2027 behind CIB momentum, no specific annual percentage quoted | Reiterated mid-single digits despite negative Q2 earning-asset growth | Guidance held despite a quarter that went backwards |
| Net charge-off framing | Guidance tied to loss content of loans 'likely to pop in and out of classified status,' with expected small inflows | 'A little above the industry's Q1 number through six months,' hope to get back under for the year | Benchmark reframed from self-referential target to industry comparison |
| ACL / problem-asset loss framing | Low leverage point on loans means 'you've got to burn through' all equity/mezz before the bank takes a loss | $22M office + $3.7M life science charge-off, 'already reserved for in the previous quarter' | ACL declining as pre-built reserves are realized, not from improving credit |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.